Pharmacoeconomics Evaluation of Insulin Degludec in the Treatment of Type 1 and Type 2 Diabetes Mellitus
10.6039/j.issn.1001-0408.2016.29.03
- VernacularTitle:德谷胰岛素治疗1型和2型糖尿病的药物经济学评价
- Author:
Haijing GUAN
;
Xiaomeng YUE
;
Jiuhong WU
- Publication Type:Journal Article
- Keywords:
Insulin degludec;
Diabetes mellitus;
Cost-effectiveness analysis;
Pharmacoeconomics
- From:
China Pharmacy
2016;27(29):4041-4046
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To systematically review the cost-effectiveness of insulin degludec(IDeg)in the treatment of type 1 diabetes mellitus(T1DM)and type 2 diabetes mellitus(T2DM). METHODS:A systematic review of literatures was conducted via PubMed,EMBase,The Cochrane Library,CNKI,Wanfang Data,VIP,IDF,ISPOR,ADA and EASD from the inception to Janu-ary 2016,to identify pharmacoeconomics evaluation literatures and non-economic studies related to IDeg in the treatment of T1DM and T2DM,compared with other basic insulin [insulin glargine(IGlar),insulin detemir(IDet),neutral protamine hagedom insulin (NPH)]. RESULTS:A total of 8 studies were included and all of them were carried out in European countries. In the short-term (one year),IDeg was more economical when compared with other basic insulin in patients with T1DM. The studies related to the long-term treatment of T1DM demonstrated different conclusions,but most of studies came to a conclusion that IDeg had good cost-effectiveness. For patients with T2DM,all of the studies demonstrated that IDeg was cost-effectiveness compared with IGlar. CONCLUSIONS:Compared with other basic insulin,IDeg can improve therapeutic efficacy and the quality of life,as well as re-duce the cost of ADR as hypoglycaemia. IDeg is a dominant or cost-effective treatment opinion.
